bluuebunny/crossref_metadata_2025_split huggingface dataset:
Determination of proliferative fractions detected by immunohistochemistry with the monoclonal antibodies to bromodeoxyuridine and Ki‐67 in malignant lymphomas
Authors: Kawauchi Kiyotaka , Sato Yuichi , Furuya Takashi , Watanabe Shaw 
Published: February 2007

AbstractThe stainability of proliferating cells with monoclonal antibodies to both bromodeoxyuridine (BrdU) and Ki‐67 were compared in 22 malignant lymphomas and six related conditions.A significant correlation was observed (r = 0.78) between the positivities of proliferating cells determined using these two monoclonal antibodies. The growth fractions determined with the antibodies were usually related to the histologic classification, but labelling index was more varied in diffuse large cell type lymphoma. BrdU labelling was well correlated with the Working Formulation, and more useful as a prognostic indicator. On the other hand, Ki‐67 was useful for broad recognition of cell proliferative ability.
In vitro chemosensitivity testing of leukemic cells: Prediction of response to chemotherapy in patients with acute non‐lymphocytic leukemia
Authors: Santini Valeria , Bernabei Pietro Antonio , Silvestro Luigi , Pozzo Orietta Dal , Bezzini Roberto , Viano Ilario , Gattei Valter , Saccardi Riccardo , Ferrini Pierluigi Rossi 
Published: February 2007

AbstractThe in vitro chemosensitivity to daunorubicin and cytosine arabinoside of blast cells derived from 35 patients affected by acute non‐lymphocytic leukemia was assessed by a semiautomated tetrazolium‐based colorimetric assay, by the use of p‐iodonitrotetrazolium violet. The results of the in vitro testing were then compared a posteriori to clinical outcome of patients, who followed a schedule of therapy which always included the drugs tested in vitro. Three dosages of drugs were employed to allow the determination of a dose‐response curve, which was obtained for all the patients. The data collected in INT assay correlated with the clinical sensitivity of patients, evaluated in terms of achievement of complete remission. For the dosage of ARA‐C 500 ng/ml it was possible to establish a significant cutoff between responders and non‐responders to therapy, while an acceptable distribution of sensitivity/resistance prediction was found for DNR 500 ng/ml and 5 μg/ml. Present results, together with rapid and easy execution of the test, encourage the use of INT assay in screening leukemic patients' sensitivity to antiblastic drugs before treatment or, in case of resistance to classical chemotherapy, in detecting individual sensitivity to alternative drugs.
Hairy cell leukemia—mediastinal involvement. A report of two cases and review of the literature
Authors: Malik S. T. A. , Amess J. , D'Ardenne A. J. , Lister T. A. 
Published: February 2007

AbstractThe clinical features of two patients with hairy cell leukemia involving the mediastinum are described. Both patients presented with acute chest pain 2‐3 months prior to diagnosis being made. In one patient mediastinal disease was recorded only by computerized tomography of the thorax. There was good response of mediastinal disease to alpha‐interferon in both patients, in spite of persisting bone marrow involvement with hairy cell leukemia.
Agnogenic myeloid metaplasia (AMM)—correlation of bone marrow lesions with laboratory data: A longitudinal clinicopathological study on 114 patients
Authors: Thiele Juergen , Zankovich Rudolf , Steinberg Thomas , Fischer Robert , Diehl Volker 
Published: February 2007

AbstractA clinicopathological study was performed on 114 patients (46 male/68 female, median age 67 years) with the diagnosis of agnogenic myeloid metaplasia (AMM) respectively primary osteo‐myelofibrosis which was not preceded by any other or allied subtype of chronic myeloproliferative disorders. On admission patients revealed a striking variability of laboratory data as well as different histopathological features of initial bone marrow biopsies. For this reason discrimination was done into two groups based on bone marrow findings: group I patients (n = 46, 19 male/27 female) showed a hypercellular marrow without or only borderline (n = 24) to slight (n = 22) reticulin fibrosis and group II cases (n = 68, 27 male/41 female) displayed coarse bundles of collagen fibres (n = 18) frequently accompanied by osteosclerosis (n = 50). Statistical analysis of the corresponding initial hematological findings resulted in significant differences. These differences concerned also the complications occurring during the lengthy course of disease, which included a higher incidence of pancytopenia and severe marrow failure with hemorrhage and blast crisis in group II patients. However, overall survival time was not different in both groups. This may be related to the similarity of age distribution (64 resp. 65 years) and its significant association with arteriosclerotic vascular lesions. Consequently acute myocardial infarction and congestive heart failure were frequent causes of death in addition to infections due to marrow failure and blast crisis. Repeated bone marrow biopsies in 24 patients revealed an insidious transition from hypercellular lesions (group I) into advanced fibro‐osteosclerotic changes (group II) concurring with laboratory data. Therefore our discrimination into two groups of patients represents variable stages or static histological and corresponding hematologic features in the evolution of a dynamic disease process in AMM.
A risk factor for relapse in Hodgkin's disease: Female gender?
Authors: Jeffery G. M. , Colls B. M. , Robinson B. A. , Fitzharris B. M. , Atkinson C. H. 
Published: February 2007

AbstractA retrospective study of 163 patients with Hodgkin's disease treated between 1969 and 1987 was performed to identify adverse prognostic factors. One hundred and thirty‐five patients (83 per cent) attained a complete remission and 42 (31 per cent) of these have relapsed (median follow‐up—43 months). Using multivariate analysis, no independent factors predicted for the event of relapse. However, analysis of disease‐free survival revealed that females fared significantly worse than males (p <0.05) and this was independent of other prognostic variables. Female sex has not been recognized as an independent prognostic factor predictive of inferior survival and inferior disease‐free survival.
T cells in follicular centroblastic/centrocytic (cleaved follicular centre cell) lymphomas at diagnosis, relapse and transformation
Authors: Swerdlow Steven H. , Habeshaw John A. , Murray Lesley J. , Stansfeld Alfred G. 
Published: February 2007

AbstractAlthough T cells are often a prominent component of follicular (± diffuse) centroblastic/centrocytic (cleaved follicular centre cell—FCC) lymphomas (CB/cc/F±D), their evolution during the course of the disease and prognostic significance are uncertain. A total of 127 histopathologic and immunophenotypic studies from 77 patients with at least one histologic diagnosis of CB/cc/F±D were therefore retrospectively reviewed to address these questions. The proportion of T cells in each biopsy was analysed with reference to both histologic (diagnosis—Kiel and Lukes/Collins classification, presence of transformation, growth pattern, presence of residual mantle zones, biopsy sites) and clinical (biopsy date and number, treatment status) parameters. The actuarial survival for those patients whose first or second biopsy showed CB/cc/F±D and had immunophenotypic studies was also compared based on the proportions of T cells present.Among the biopsies which were obtained from 0 to 153 months following diagnosis, the mean proportion of T cells was 25 ± 18 per cent. The only histopathologic group that showed a significantly different proportion of T cells were lymphomas of large cleaved FCC type (38 ± 20 per cent). Although the number of T cells present varied greatly between different patients and among different biopsies in the same patients, neither biopsy number nor treatment status affected the mean proportion of T cells in CB/cc/F±D. With the exception of those biopsies from 1 to 11 months following diagnosis, the interval time between diagnosis and biopsy also did not affect the number of T cells present. Finally, the proportion of T cells in the lymphomas could not be shown to be of prognostic importance.Thus, the proportion of T cells in de novo CB/cc/F±D, at relapse or in transformation does not vary in a consistent fashion. Although extremely variable, the number of T cells present cannot be considered a feature of earlier or later disease and is not of demonstrable prognostic importance. Studies of specific subsets of T cells may provide more definite associations.
Hodgkin's disease in Hong Kong Chinese
Authors: Liang Raymond , Choi Peter , Todd David , Chan T. K. , Choy Damon , Ho Faith 
Published: February 2007

AbstractA lower incidence of Hodgkin's disease in Orientals has been recognized. Although most Hong Kong Chinese came from the Guangdong province of China, the incidence of Hodgkin's disease in Hong Kong Chinese is 9.2 per cent which is more comparable to the low figure of 6 per cent in Japan than the 32 per cent incidence in Guangdong. If this discrepancy in the ethnically similar populations is confirmed, other etiological or promoting factors must be considered. Ninety‐two Hong Kong Chinese patients (54 males and 38 females) with Hodgkin's disease were reviewed. The median age was 34 years (range 5–79 years). The histology was lymphocyte predominant in nine (10 per cent), nodular sclerosing in 34 (37 per cent), mixed cellularity in 29 (31 per cent), lymphocyte depleted in nine (10 per cent) and unclassified in 11 (12 per cent). Seventeen per cent had stage Ia disease, 2 per cent Ib, 15 per cent IIa, 11 per cent IIb, 11 per cent IIIa, 9 per cent IIIb, 11 per cent IVa and 24 per cent IVb. Twenty‐five of them (27 per cent) were staged by laparotomy. Twelve patients (13 per cent) had bulky disease. Identical to the pattern observed in Caucasians, our patients had an apparent biomodal age distribution, a male predominance and similar distribution of histological subtypes according to the Rye classification. The absence of an early peak in young adulthood and the lower incidence of the nodular sclerosing subtype reported in the Japanese was not observed in our patients.A variety of treatments were given to the 92 patients. Most of the patients with stage I–II disease received radiotherapy except for those with B symptoms, bulky disease or lymphocyte depleted histology, who received chemotherapy with or without radiotherapy. All patients with stage III–IV disease received chemotherapy with or without radiotherapy except for two patients with stage IIIa disease who had total nodal irradiation only. The multivariate analysis revealed that Ann Arbor staging was a significant independent factor determining the disease‐free survival of patients in complete remission and the overall survival of all patients. Age was the other independent variable significantly determining the overall survival.
Triple combination of retinoic acid + low concentration of cytosine arabinoside + hexamethylene bisacetamide induces differentiation of human aml blasts in primary culture
Authors: Hassan H. T. , Rees J. K. H. 
Published: February 2007

AbstractDifferentiation induction therapy provides an alternative therapeutic approach for patients with acute myeloid leukemia (AML) who are either unsuitable for or unresponsive to conventional cytotoxic chemotherapy. The effect of a triple combination of retinoic acid (RA) + low concentration of cytosine arabinoside (Ara‐C) + hexamethylene bisacetamide (HMBA) on differentiation of blasts from 24 AML patients was studied. Non‐adherent mononuclear cells were seeded at a concentration of 5 × 105 cells per ml in 24‐well tissue culture plates containing RPMI 1640 culture medium with 20 per cent fetal calf serum and 10 per cent 5637‐conditioned medium and incubated with 10−6 M retinoic acid, 10−6 M cytosine arabinoside and or 2 mM hexamethylene bisacetamide for six days at 37 °C in a humidified incubator under 5 per cent CO2. Morphological, cytochemical and functional differentiation into mature cells were induced in blasts from 22 out of the 24 AML patients following exposure to the triple combination of 10−6 M RA + 10−6 M Ara‐C+2 mM HMBA in primary culture. These effective results justify a clinical trial of such triple combination for AML patients who are either unsuitable for or unresponsive to conventional cytotoxic chemotherapy.
Prognostic significance of flow cytometry studies in B‐cell non‐hodgkin lymphoma
Authors: Rehn Suzanne , Glimelius Bengt , Strang Peter , Sundström Christer , Tribukait Bernhard 
Published: February 2007

AbstractThe prognostic relevance of flow cytometric DNA measurements of lymph node biopsies in relation to histopathology according to the Kiel classification, stage, age and presence or absence of B‐symptoms was investigated in 106 patients with non‐Hodgkin lymphomas (NHL) of proven B‐cell type. Biopsies were taken at diagnosis before treatment. The mean proportion of cells in S‐phase was significantly lower in the 76 patients with a ‘low grade’ NHL (4.4 per cent) than in the 30 patients with a ‘high grade’ NHL (13.0 per cent) (p<0.0001). High S‐phase rates were associated with a poor prognosis within the whole material (p<0.01) and within the group of ‘high grade’ NHL (p<0.05). In the subgroup CB‐CC lymphomas of ‘low grade’ NHL, the prognostic value of the S‐phase rate was stronger than any other investigated parameter (p<0.05). In multivariate analyses, the S‐phase rate gave, in several subgroups, independent prognostic information, besides clinico‐pathological variables.
Acute myeloid leukemia in elderly adults
Authors: Tucker J. , Thomas A. E. , Gregory W. M. , Ganesan T. S. , Malik S. T. A. , Amess J. A. L. , Lim J. , Willis L. , Rohatiner A. Z. S. , Lister T. A. 
Published: February 2007

AbstractOne hundred and fifteen previously untreated adults aged over 60 years were referred to St Bartholomew's Hospital between 1978 and 1986 for management of acute myeloid leukemia (AML). Twenty‐seven patients received symptomatic or palliative treatment only because combination chemotherapy was considered inappropriate.Eighty‐eight patients received intensive chemotherapy with curative intent. There was a 48 per cent ‘early death’ rate and a 24 per cent incidence of resistant disease; complete remission (CR) was achieved in 25 88 patients (28 per cent). By multivariate analysis, a blast count < 50 × 109/1 at presentation was the only factor predictive for achievement of CR whilst the latter and a presentation blast count <50 × 109/1 predicted for superior survival.Treatment was often curtailed on account of unacceptable toxicity; only 2/88 patients received the planned six cycles of treatment. Two patients died in CR. Four patients are alive in first CR at 3–9 years from treatment; one is alive in second CR following meningeal relapse. Overall survival was significantly worse than that of a contemporaneous group of adults aged 15–59 years treated at this hospital, but duration of CR was comparable.There are great difficulties involved in the intensive treatment of AML in elderly adults, but the major survival benefit gained by achieving CR should stimulate the search for better tolerated but still curative regimens.
Treatment of low‐grade non‐Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial
Authors: Lepage E. , Sebban C. , Gisselbrecht C. , Coiffier B. , Harousseau J. L. , Bryon P. A. , Boiron M. 
Published: February 2007

AbstractFrom 1981 to 1984 a randomized clinical trial was conducted to evaluate the role of doxorubicin in low grade malignancy non‐Hodgkin's lymphoma (NHL). One hundred and thirteen patients were treated by an induction regimen including cyclophosphamide 400 mg/m2day 1 and 8, vincristine 1.4 mg/m2day 1 and 8, procarbazine 80 mg/m2day 1 to 14, prednisone 60 mg/m2day 1 to 5 (PCOP regimen) randomly associated to doxorubicin: 20 mg/m2day 1 and 8 (PACOP regimen). Maintenance therapy consisted of 12 monthly courses of chlorambucil 10 mg/m2for 5 days or association of cyclophosphamide 300 mg/m2for 3 days, vincristine 1.4 mg/m2day 1 and prednisone 60 mg/m2for 5 days. Complete response (CR) was obtained in 51 patients (45 per cent), in 30 patients after induction regimen and in 21 patients after maintenance therapy, without difference according to regimens. Bone marrow involvement (p=0.02) and number of involved nodal sites (p=0.001) were found to influence probability of achieving CR. The median time to progression was estimated to 39 months without difference between regimens. Median overall survival is not reached with a median follow‐up of 53 months. Multivariate regression analysis permits observation of negative influence on survival of three parameters: initial bone marrow involvement, age over 50 years and incomplete response to treatment. The initial adjunction of doxorubicin did not seem to influence the appearance of histologic progression.
Change in tumour cell‐lymphocyte interactions with age
Authors: Ghoneum Mamdooh , Grewal Iqbal S. 
Published: February 2007

AbstractIn the present study, we analysed the phenomenon of leukophagocytosis by tumour cells with respect to the age of the animal. Splenic leukocytes from C3H mice at different ages were depleted of macrophages and used as targets against tumour effector cells. Tumour cell lines P388D1, a macrophage lymphoma of mouse origin and LAZ‐559, a B cell lymphoma of human origin, were cultured with leukocytes at 37°C and 5 per cent CO2 for 4 h and the percentage of phagocytic tumour cells were examined in cytospin preparations. The results demonstrated that the phagocytic activity of P388D1 cells was 10, 6, 3 and 28 per cent against 1, 2, 6, and 35 week‐old mice respectively; while LAZ‐559 showed lower activity; 5, 3, 1·5 and 17 per cent against leukocytes of corresponding ages. Susceptibility of old leukocytes to phagocytosis could be detected as early as 30 min after culture with tumour cells, and increased with increasing incubation period. At 4 h, phagocytosis by tumour cells resulted in 38 and 29 per cent reduction in the leukocyte number postculture with P388D1 and LAZ‐559 cells respectively. We postulate that an age‐related decline in immune function is associated with increased level of phagocytic tumour cells, and that the loss of leukocytes may have adverse effects on the immune system.
RESIDUAL MEDIASTINAL WIDENING FOLLOWING THERAPY IN HODGKIN'S DISEASE
Authors: Orlandi Ester , Lazzarino Mario , Brusamolino Ercole , Caldera Daniela , Morra Enrica , Dore Roberto , Giulio Giuseppe Di , Bernasconi Carlo 
Published: February 2007

AbstractThe chest radiograms (CXR) of 102 patients with Hodgkin's disease presenting with mediastinal involvement at diagnosis were reviewed to assess the incidence and relevance of residual mediastinal abnormalities after therapy. All patients had completed planned treatment and had no evidence of persisting extramediastinum disease at restaging. Thirty‐nine cases (38 per cent) showed residual mediastinal widening at the end of therapy (minimal changes in nine and measurable changes in 30 cases). Neither presenting features nor treatment modality correlated with residual mediastinal mass on chest X‐ray. The isolated intrathoracic relapse rate was 11 per cent for patients with normal mediastinum following therapy, as compared with 20.5 per cent for those with residual widening; this difference did not reach statistical significance (p = 0.3). The persistence of mediastinal abnormalities was associated with a trend towards a higher risk of intrathoracic relapse for patients with initial bulky disease (p < 0.05) and for those with B symptoms (p = 0.07). Using thoracic CT scan for restaging (56 patients), the residual mediastinum rate rose to 70 per cent; the predictability of local relapse with this procedure was not greater than with conventional X‐ray study.
Secondary central nervous system involvement by non‐Hodgkin's lymphoma: The risk factors
Authors: Liang Raymond , Chiu Edmond , Loke S. L. 
Published: February 2007

AbstractThe risk of secondary central nervous system (CNS) was estimated in 833 cases of non‐Hodgkin's lymphoma diagnosed between January 1975 and December 1988. Fifty‐one of them had CNS disease (51/833, 6.1 per cent). No case of low grade lymphoma developed CNS disease. However, 6.5 per cent and 16.7 per cent of patients with intermediate and high grade lymphomas, respectively, had secondary CNS involvement. Stage IV disease and the presence of B symptoms were also associated with an increased risk of CNS disease.Significantly higher incidence of CNS disease was seen in patients with lymphoma involving orbit (43 per cent), testis (40 per cent), peripheral blood (33 per cent), bone (29 per cent), nasal/paranasal sinuses region (23 per cent) and bone marrow (20 per cent). CNS prophylaxis is recommended to patients with an increased risk of CNS disease.
Management of advanced stage intermediate grade non‐Hodgkin's lymphomas
Authors: Liang Raymond H. S. , Chiu Edmond K. W. , Chan T. K. , Todd David , Loke S. L. 
Published: February 2007

AbstractThe treatment result of 271 cases of advanced stage intermediate grade lymphoma were reviewed. Ninety‐four patients received CHOP chemotherapy, 45 BACOP and 17 m‐BACOD. The clinical characteristics of the three groups of patients were comparable. Patients receiving CHOP had a complete response (CR) rate of 60 per cent, the disease‐free survival of CR patients was 31 per cent at 5 years. The overall survival following CHOP chemotherapy was 38 per cent at 5 years. The use of the BACOP or m‐BACOD regime did not appear to improve significantly the prognosis of these patients. Clinical staging, B symptoms, age and serum lactate dehydrogenase level were the most important independent prognostic factors.
Histopathological study of bone marrow biopsies in 30 cases of T‐cell lymphoma with clinical, biological and survival correlations
Authors: Caulet S. , Delmer A. , Audouin J. , Le Tourneau A. , Bernadou A. , Zittoun R. , Diebold J. 
Published: February 2007

AbstractForty‐five bone marrow (BM) biopsies have been studied in 30 T‐cell malignant lymphoma (ML). According to the updated Kiel classification, these ML comprised 12 low grade ML and 18 high grade ML. BM involvement was not significantly more frequent in low grade ML (41.6 per cent) than in high grade (33.3 per cent). This involvement was discovered in 85 per cent of the cases at the time of diagnosis. A correlation was found between BM and other visceral localizations for histological type in all cases. Infiltrates principally showed a nodular pattern in low grade and a diffuse pattern in high grade ML. Hematopoietic hyperplastic reaction was frequent (66.6 per cent) not correlated to involvement. Clinical staging showed extensive spreading. Our patients had an overall median survival of 40 months, worse in high grade ML (median: 19 months) than in low grade ML (41 months) but not statistically different (p = 0.25). Extranodal localizations are a significant criteria for poor prognosis (p = 0.018). Among them, BM involvement appears to be the most significant criteria (Cox model, p = 0.006). Patients with BM localization had a median survival of 9 months contrasting with 40 months in patients without BM localization (p = 0.007).Thus, BM biopsy is useful for the diagnosis of patients with T‐ML and essential to establish the prognosis.